Clinical trials: Crohn Disease (CD)
Chronic Pain, Crohn Disease
Group ACT for CD Pain- a Feasibility Study
Pain is a common symptom of inflammatory bowel disease (IBD) and has a significant impact on patient quality of life. Pain will frequently be the presenting complaint and is experienced throughout the disease course.
- Trial name
- NCT05418062
- Testing
- Acceptance and commitment therapy (ACT)
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- King's College London
Crohn Disease (CD), Crohns Disease
Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis
This research study looks at how safe and effective a medicine called Mirikizumab is for treating older adults (aged 60 and above) who have moderate to severe Crohn's disease (CD) or ulcerative colitis (UC).
- Conditions
- Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
- Trial name
- NCT07059130
- Testing
- Mirikizumab
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Rubix LS
Intestinal Tuberculosis, Pulmonary Tuberculosis
Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease
One aims to devise a method for the screening and differentiation of intestinal tuberculosis and Crohn's Disease. Additionally, one aims to detect and survey multidrug resistant TB.
- Conditions
- Intestinal Tuberculosis, Pulmonary Tuberculosis, Crohn's Disease
- Trial name
- NCT01503099
- Where
- 2 sites in India, Norway
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Lovisenberg Diakonale Hospital
CD - Crohn's Disease, Stricture; Bowel
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
This study intends to select patients with confirmed moderate-to-severe Crohn's disease (CD) and obstructive symptoms of intestinal stenosis, who have clear evidence of lumen stenosis caused by the disease itself through…
- Conditions
- CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease
- Trial name
- NCT07444060
- Testing
- Guselkumab (GUS), Ustekinumab (UST)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ulcerative Colitis (UC), Crohn Disease (CD)
Exploring Multiple Self-Help Interventions to Promote Self-Efficacy and Overcome Disability
EMPOWER-IBD aims to identify behavioral interventions to strengthen patients' self-efficacy for self-management as a mechanism to reduce IBD-related disability.
- Trial name
- EMPOWER-IBD (NCT06646757)
- Testing
- APP, CBT, HELP
- Where
- United States
- Volunteers
- 803 people
- Sponsor
- University of Pennsylvania
Radiomics, Multi-omics
Neurophenotype Predicts CD Disease Progression
The goal of this observational study is aimed to develop a novel multimodal neuroimaging-based model to characterize the neurophenotype of Crohn's Disease patients and assess its ability for predicting disease progression, using…
- Trial name
- NCT06452550
- Testing
- Logistic regression (LR) prediction models
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Severe Crohn's Diease
CD Patients Immune Status Evaluation
Using single cell sequencing method to evaluate and compare the immune status of patients with severe CD.
- Trial name
- NCT04135482
- Testing
- colonic tissue biopsy
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Crohn's Disease, Dietary Modification
The Impact of "Crohn's Disease-TReatment-with-EATing" Diet and Exclusive Enteral Nutrition on Healthy Gut Bacteria
Current evidence suggests that the gut microbiota and dietary influences are as important as genetics in the aetiology of Crohn's disease (CD).
- Trial name
- NCT02426567
- Testing
- Exclusive Enteral Nutrition (EEN), Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Ulcerative Colitis, Crohn's Disease
A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)
This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A.
- Trial name
- NCT02749630
- Testing
- UTTR1147A
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Colon Neoplasms, Crohn Disease (CD)
Feasibility Study of the SEGER Device in Laparoscopic Gastrointestinal Surgery
This is a first-in-human feasibility study designed to evaluate the safety and performance of the SEGER device in patients undergoing elective laparoscopic gastrointestinal surgery requiring intracorporeal anastomosis.
- Conditions
- Colon Neoplasms, Crohn Disease (CD), Obesity & Overweight
- Trial name
- SEGER-FIH (NCT07508592)
- Testing
- SEGER Device
- Where
- El Salvador
- Volunteers
- 10 people
- Sponsor
- Seger Surgical Solutions
Crohn's Disease (CD)
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab.
- Trial name
- SEQUENCE (NCT04524611)
- Testing
- Risankizumab, Ustekinumab
- Where
- 300 sites in United States, Argentina and 29 more
- Volunteers
- 527 people
- Sponsor
- AbbVie
Ulcerative Colitis (UC), Crohn Disease (CD)
Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
Crohn\'s Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory…
- Trial name
- NAVIGATE (NCT06606808)
- Testing
- Risankizumab-800CW 4.5 mg, Risankizumab-800CW 15 mg, Risankizumab-800CW 25 mg
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- University Medical Center Groningen
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)
The purpose of this study is to evaluate the efficacy and safety of ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
- Trial name
- CARMEN CD 305 (NCT03559517)
- Testing
- Ontamalimab
- Where
- 138 sites in United States, Australia and 14 more
- Volunteers
- 30 people
- Sponsor
- Shire
Crohn's Disease (CD)
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab.
- Trial name
- NCT04779320
- Testing
- Vedolizumab IV
- Where
- 96 sites in United States, Australia and 16 more
- Volunteers
- 120 people
- Sponsor
- Takeda
Irritable Bowel Disease, Ulcerative Colitis (UC)
Health-Related Quality of Life Among Patients With Inflammatory Bowel Disease
The primary aim of this study is to assess HRQOL and its associated factors among people with IBD. The target sample will be 385 adult patients diagnosed with IBD (both Crohn's Disease and Ulcerative Colitis).
- Conditions
- Irritable Bowel Disease, Ulcerative Colitis (UC), Crohn Disease (CD)
- Trial name
- NCT07436910
- Where
- Egypt
- Volunteers
- 385 people
- Sponsor
- Cairo University
Inflammatory Bowel Diseases, Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's…
- Trial name
- GARNET (NCT06226883)
- Testing
- MORF-057
- Where
- 225 sites in United States, Australia and 26 more
- Volunteers
- 385 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Crohn's Disease
A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective Humira (adalimumab) is in treating moderately to severely active CD in China.
- Trial name
- NCT05394805
- Where
- 10 sites in China
- Volunteers
- 156 people
- Sponsor
- AbbVie
Inflammatory Bowel Diseases (IBD), Remission of IBD
VIBRANT-IBD: Brain Effects of Non-Invasive Vagus Nerve Stimulation in IBD Remission
The VIBRANT-IBD study is a pilot, prospective, single-arm feasibility study investigating the effects of non-invasive vagus nerve stimulation (nVNS) in adults with inflammatory bowel disease (IBD) in clinical remission.
- Conditions
- Inflammatory Bowel Diseases (IBD), Remission of IBD, In Adults, Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
- Trial name
- VIBRANT-IBD (NCT07636304)
- Testing
- Non-invasive vagus nerve stimulation (nVNS)
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- University of Gdansk
Crohn Disease, Recurrence
Comparison of Two Stapled Antimesenteric Anastomosis for CD: a Randomized Control Trial Study
The postoperative recurrence of Crohn's diseases (CD) remains high. Stapled anti-mesenteric functional end-to-end anastomosis was safe for CD patients. Its impact on the postoperative recurrence of CD was unknown.
- Trial name
- NCT05658081
- Testing
- Kono-S group, Side-to-side group
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Jinling Hospital, China
Crohn Disease (CD)
AI-Assisted MRE for Intestinal Fibrosis in Crohn's Disease
Intestinal fibrotic strictures represent a severe complication of Crohn's disease (CD), affecting over half of the patients. Despite the continuous emergence of novel medications, effective treatment options remain scarce.
- Trial name
- NCT06858553
- Where
- 5 sites in China
- Volunteers
- 234 people
- Sponsor
- Minhu Chen